ABT-773: a new ketolide antibiotic.
ABT-773 is a new semisynthetic derivative of erythromycin A, the ketolide class of broad spectrum antibacterial agents, in Phase II development by Abbott. With good broad spectrum activity against Gram-positive, some Gram-negative organisms and intracellular bacteria, ABT-773 is being developed as a respiratory agent. Structural changes in the ketolide class agents such as ABT-773 provides expanded activity in vitro against macrolide-resistant strains of Streptococcus pneumoniae and improved activity against MLS(B) (macrolide-lincosamide-streptogramin) constitutive expressing streptococci.
Dougherty
T J
TJ
Bristol-Myers Squibb Pharmaceutical Research Institute, Department of Microbiology, 5 Research Parkway, Wallingford, CT 06492, USA.
Barrett
J F
JF
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004917:Erythromycin / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D048628:Ketolides
D000900:Anti-Bacterial Agents; D048628:Ketolides; D004917:Erythromycin; C405499:cethromycin